Previously, Espinoza-Sánchez and Götte have discussed that cell surface proteoglycans are attractive targets for cancer and have presented current developments for immunotherapy targeting glypicans in cancer (Espinoza-Sánchez and Götte 2020), where studies and clinical trials have shown great potential. This evidence concerns the gene GPC1 and cancer.